Compare EOD & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EOD | CCCC |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 252.4M | 240.3M |
| IPO Year | N/A | 2020 |
| Metric | EOD | CCCC |
|---|---|---|
| Price | $5.98 | $2.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 118.1K | ★ 1.7M |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 9.28% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $30,108,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.73 | $1.09 |
| 52 Week High | $4.71 | $4.89 |
| Indicator | EOD | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 68.59 | 51.91 |
| Support Level | $5.58 | $2.49 |
| Resistance Level | $5.89 | $2.84 |
| Average True Range (ATR) | 0.07 | 0.19 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 100.00 | 52.72 |
Allspring Global Dividend Opportunity Fund is a diversified closed-end management investment company. Its primary investment objective is to seek a high level of current income. The fund's secondary objective is the long-term growth of capital. The fund allocates its assets between two separate investment strategies or sleeves. Under normal market conditions, the fund allocates approximately 80% of its total assets to an equity sleeve comprised of common stocks.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.